medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2016, Número 01

<< Anterior Siguiente >>

Ginecol Obstet Mex 2016; 84 (01)


Efecto de la corifolitropina alfa en pacientes de fertilización in vitro-ICSI con falla previa en un protocolo de FSH/HMG: experiencia preliminar en México

Barroso-Villa JG, Colín-Valenzuela A, Valdespín-Fierro C, Ávila-Lombardo R, Estrada-Gutiérrez G

Idioma: Español
Referencias bibliográficas: 22
Paginas: 7-13
Archivo PDF: 408.94 Kb.


RESUMEN

Antecedentes: la aplicación diaria de medicamentos, en muchas ocasiones de dosis altas, es un factor de estrés para la pareja infértil. Durante la última década la corifolitropina alfa ha permitido un esquema más amigable, con resultados comparables a los protocolos tradicionales (FSHr/HMG).
Objetivo: comparar los resultados de la corifolitropina alfa en pacientes con un ciclo previo de FIV-ICSI con un esquema de estimulación ovárica tradicional.
Material y Método: estudio observacional, retrospectivo, tipo cohorte al que se incluyeron parejas infértiles.
Resultados: se encontraron diferencias significativas en las dosis utilizada de FHSr (2023U/total ±712 vs 636 U/total±307) y en la concentración sérica de estradiol el día del disparo con HGCr (1972 pg/dL ± 1152 vs 1107 pg/dL ± 775). Se encontró una tasa superior de embarazo con corifolitropina alfa quizá debido a que se trató de un segundo intento de fertilización in vitro.
Conclusiones: los resultados reproductivos en un ciclo de estimulación ovárica con corifolitropina son comparables con los resultados de un ciclo se estimulación ovárica tradicional. Es importante ampliar la experiencia en la indicación del fármaco en pacientes mexicanas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The ESRHE Capri workshop group. Intracytoplasmic sperm injection (ICSI) in 2006: evidence and evolution. Human Reprod Update 2007; 13:515-126.

  2. Bosch E, Ezcurra D. Individualized controlled ovarian stimulation (iCOS): maximizing success rates for assisted reproductive technology patients. Reprod Biol Endocrinol 2011; 9: 82.

  3. Ferraretti A and Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod 2014; 29:1842-1845.

  4. Ferraretti AP, Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of poor ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reprod 2011; 27:1616-1624.

  5. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 1992;89:4304-4308.

  6. Duijkers IJ, KIipping C, Boerrigter PJ, Machielsen CSM, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary- suppressed females. Hum Reprod 2002; 17:1 987-1993.

  7. Fauser BCJM, Mannaerts BMJL, Devroyey P, Leader A, Biome I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle- stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15: 309-321.

  8. De Greef R, Struijs M, de Haan A, Marintcheva-Petrova M, Mannaerts B. Dose selection of Org 36286 (corifollitropin alfa) using pharmacokinetic and dynamic modeling and simulation. Hum Reprod. 2007; 22(suppl 1): i39.

  9. Norman R, Zegers F, Salle B, Elbers J, Heijnen E, Marintcheva M, Mannaerts B. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reprod 2011; 26:2200-2208.

  10. Devroey P. Boostanfar R, Koper NP, et al: on behalf of the Engage Investigators. A double-blind, non-inferiority RCTcomparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24:3063-3072.

  11. Hillensjo T on behalf of The ELONVA Ensure Study Group. A comparison of ELONVA versus daily recombinant FSH (Puregon®) in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Presented at the 25th Annual Meeting of the European Society of Human Reproduction and Embryology; June 28-July 1,2009; Amsterdam, The Netherlands.

  12. Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B. First results with ELONVA in a long GnRH agonist protocol. (ESHRE Oral Presentation O-283) Hum Reprod. 2009; 24(suppl 1): i114.

  13. Bouloux PM, Handelsman DJ, Jockenhövel F, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001; 16:1592-1597.

  14. The Corifollitropin alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008; 23:2484-2492.

  15. Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant folliclestimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization Group ll anovulatory infertility. J Clin Endocrinol Metab 2004; 89:6297-6304.

  16. Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC. First live birth after ovarian stimulation using a chimeric long-acting human recombinant folliclestimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil Steril 2003; 79:621-623.

  17. Devroey P. Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant folliclestimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004; 89: 2062-2070.

  18. C. Blockeel, N.P. Polyzos, L. Derksen, M. De Brucker, V. Vloeberghs, A. van de Vijver, M. De Vos, and H. Tournaye. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot study. Hum Reprod 2014; 29: 1500-1507.

  19. Verbost P, Sloot W, Rose U, Leeuw R, Hanssen R, Verhejden G. Pharmacologic profiling of corifollitropin alfa, the fist developed sustained follicle stimulant. European J Pharmacol 2011; 651:227-233.

  20. Mahmoud Youssef MA1, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Feril Steril 2012; 97:876-885.

  21. Polyzos NP1, Devos M, Humaidan P, Stoop D, Ortega- Hrepich C, Devroey P, Tournaye H. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril 2013; 99:422-427.

  22. Bonduelle M, Mannaerts B, Leader A, Bergh C, Passier D, Devroey P. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Hum Reprod 2012; 27:2177-2185.




2020     |     www.medigraphic.com